Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
CAMX
Cambiar Aggressive Value ETF
34.7
9
USD
+0.01%
Market Price
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.84%
Monthly Change
+3.54%
6 month change
+4.95%
Year Change
+6.75%
Previous Close
34.7
9
Open
34.8
4
Low
34.7
9
High
34.8
4
Markets
US ETFs
CAMX
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
HON
HONEYWELL INTERNATIONAL INCORPORATION
1.75 M
7 213.00
2.58%
AXP
AMERICAN EXPRESS COMPANY
1.72 M
5 123.00
2.53%
CNC
CENTENE CORPORATION
1.61 M
25.87 K
2.36%
MAS
MASCO CORPORATION
1.61 M
22.48 K
2.36%
HONEYWELL AEROSPACE INC.
1.49 M
7 213.00
2.19%
LH
LABCORP HOLDINGS INC.
1.48 M
4 775.00
2.17%
STZ
CONSTELLATION BRANDS, INC.
1.43 M
10.94 K
2.09%
DEO
DIAGEO PLC
1.31 M
14.92 K
1.93%
I
INGM
INGRAM MICRO HOLDING CORPORATION
1.30 M
46.05 K
1.91%
CVX
CHEVRON CORPORATION
1.21 M
6 168.00
1.78%
VSNT
Versant Media Group, Inc.
1.21 M
33.53 K
1.77%
FEDEX FREIGHT HOLDING COMPANY, INC.
1.16 M
8 257.00
1.70%
1
2
News
Uber Axes 3,300 Jobs to Build Its Autonomous Future - Uber Technologies (NYSE:UBER)
Camurus reports Q4 revenue miss, lowers 2026 outlook
FDA accepts Camurus’ resubmission for acromegaly treatment Oclaiz
Camurus Q3 2025 slides: Revenue up 18% but stock dips on lowered guidance
Camurus cuts 2025 revenue forecast as Buvidal sales miss estimates
Camurus Q2 2025 slides reveal 52% revenue surge and key regulatory milestones
Earnings call transcript: Camurus AB Q2 2025 earnings beat expectations
Camurus Q2 2025 slides: Record revenue and profit amid product portfolio expansion
Camurus’ POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal ® incretins
Camurus Q1 2025 slides: record profitability despite market challenges